Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 0.47 |
| ▸ | AR | P10275 | 6/20 | 0.47 |
| ▸ | DDB1 | Q16531 | 8/20 | 0.45 |
| ▸ | HPGDS | O60760 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | CCR3 | P51677 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.39 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29547143 | 1.00 | CRBN (0.47) | CRBNARDDB1HPGDSHRH1 | |
| SCHEMBL24379304 | 1.00 | CRBN (0.47) | CRBNARDDB1HPGDSHRH1 | |
| SCHEMBL29546706 | 0.90 | CRBN (0.47) | CRBNARDDB1HPGDSHRH1 | |
| SCHEMBL24379366 | 0.90 | CRBN (0.47) | CRBNARDDB1HPGDSHRH1 | |
| SCHEMBL29546787 | 0.90 | CRBN (0.47) | CRBNARDDB1HPGDSHRH1 | |
| SCHEMBL22661312 | 0.90 | CRBN (0.42) | CRBNARDDB1HPGDSEGFR | |
| SCHEMBL23129033 | 0.90 | CRBN (0.42) | CRBNARDDB1HPGDSEGFR | |
| SCHEMBL24411066 | 0.84 | CRBN (0.48) | CRBNDDB1 | |
| SCHEMBL20075854 | 0.84 | CRBN (0.48) | CRBNDDB1 | |
| SCHEMBL29632695 | 0.84 | CRBN (0.48) | CRBNDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260053932-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS INC (US) | 2026-02-26 | — | — | US | disclosed |
| EP-4232445-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR PROTEIN | Arvinas Operations, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| WO-2022087125-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR PROTEIN | ARVINAS OPERATIONS, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260053932-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AND ASSOCIATED METHODS OF USE | ADRM1, AR, CRBN | CRBN 3/4885AR 2/4885DDB1 708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.